Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-dose Interferon Alfa-2b

This publication has 22 references indexed in Scilit:

• Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma
  Journal of Clinical Oncology, 2004
• Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
  Cancer Treatment Reviews, 2003
• Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma
  Nature Reviews Cancer, 2003
• Epidemiology of malignant melanoma
  Surgical Clinics of North America, 2003
• High frequency of BRAF mutations in nevi
  Nature Genetics, 2002
• Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial
  Journal of Clinical Oncology, 2002
• Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma
  The Journal of Experimental Medicine, 2002
• M-Vax: an autologous, hapten-modified vaccine for human cancer
  Expert Opinion on Biological Therapy, 2002
• Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
  The Lancet, 2001
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases
  The Lancet, 1998